Login to Your Account



Bayer wins battle for Nexavar against Natco; will it win the war?

By Cornelia Zou
Staff Writer

Wednesday, April 9, 2014

HONG KONG – An Indian court has banned exports of a generic cancer drug, giving Bayer Healthcare Pharmaceuticals Inc. a first victory in an ongoing lawsuit to protect the patent of targeted cancer drug Nexavar (sorafenib), one of its star performers co-developed with Onyx Pharmaceuticals Inc.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription